NKTR Stock Overview
A biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Nektar Therapeutics Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.13 |
| 52 Week High | US$1.93 |
| 52 Week Low | US$0.41 |
| Beta | 0.60 |
| 11 Month Change | -4.24% |
| 3 Month Change | -10.32% |
| 1 Year Change | 94.02% |
| 33 Year Change | -92.92% |
| 5 Year Change | -94.38% |
| Change since IPO | -69.87% |
Recent News & Updates
Recent updates
Some Nektar Therapeutics (NASDAQ:NKTR) Shareholders Look For Exit As Shares Take 35% Pounding
Jun 19
There's No Escaping Nektar Therapeutics' (NASDAQ:NKTR) Muted Revenues Despite A 44% Share Price Rise
Feb 15Nektar Therapeutics' (NASDAQ:NKTR) Business And Shares Still Trailing The Industry
Dec 31Is Nektar Therapeutics (NASDAQ:NKTR) In A Good Position To Invest In Growth?
Nov 06Is Nektar Therapeutics (NASDAQ:NKTR) In A Good Position To Invest In Growth?
Apr 24Here's Why Nektar Therapeutics (NASDAQ:NKTR) Must Use Its Cash Wisely
Jan 24Is Nektar Therapeutics (NASDAQ:NKTR) In A Good Position To Deliver On Growth Plans?
Aug 19Nektar: Time To Abandon Ship
Jul 17Nektar promotes internal executive to CFO role
Jul 01We Think Nektar Therapeutics (NASDAQ:NKTR) Needs To Drive Business Growth Carefully
May 11After A High-Profile Failure In Melanoma, Nektar Therapeutics' Value Shifts To Its Early-Stage Pipeline
Apr 04Analysts Just Made A Major Revision To Their Nektar Therapeutics (NASDAQ:NKTR) Revenue Forecasts
Mar 09Nektar Therapeutics: Beaten Down By 2020
Jan 26We Think Nektar Therapeutics (NASDAQ:NKTR) Can Easily Afford To Drive Business Growth
Jan 13Nektar Therapeutics (NASDAQ:NKTR) Analysts Just Trimmed Their Revenue Forecasts By 11%
Dec 09Shareholder Returns
| NKTR | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -11.7% | -2.4% | -2.7% |
| 1Y | 94.0% | 17.4% | 21.3% |
Return vs Industry: NKTR exceeded the US Pharmaceuticals industry which returned 21.4% over the past year.
Return vs Market: NKTR exceeded the US Market which returned 21.1% over the past year.
Price Volatility
| NKTR volatility | |
|---|---|
| NKTR Average Weekly Movement | 10.8% |
| Pharmaceuticals Industry Average Movement | 9.9% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: NKTR's share price has been volatile over the past 3 months.
Volatility Over Time: NKTR's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 137 | Howard Robin | www.nektar.com |
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system’s natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.
Nektar Therapeutics Fundamentals Summary
| NKTR fundamental statistics | |
|---|---|
| Market cap | US$228.26m |
| Earnings (TTM) | -US$177.08m |
| Revenue (TTM) | US$93.16m |
2.2x
P/S Ratio-1.2x
P/E RatioIs NKTR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NKTR income statement (TTM) | |
|---|---|
| Revenue | US$93.16m |
| Cost of Revenue | US$37.99m |
| Gross Profit | US$55.17m |
| Other Expenses | US$232.25m |
| Earnings | -US$177.08m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.96 |
| Gross Margin | 59.22% |
| Net Profit Margin | -190.09% |
| Debt/Equity Ratio | 134.9% |
How did NKTR perform over the long term?
See historical performance and comparison